Arvinas shocked the market with its latest quarterly filing, reporting Q2 2026 revenue of US$249.7 million and net income of US$169.4 million, a sharp shift from losses a year earlier, yet the share chart tells a different story. Investors who held Arvinas from the start of the year are down 38.2%, including dividends. If you had put money to work on 1 January 2026 based on those earlier narratives, how do these new numbers challenge the original expectation you set?
The easy part of this move is behind Arvinas. Zero in on 35 high quality undervalued stocks for companies trading below our estimates.
The Argument You Would Have Been Weighing Up On Arvinas
The shares cost US$11.86 at the start of the period, so any view on Arvinas had to begin with what that price already assumed about its future.
The bullish narrative pointed to a Fair Value of US$17.44, a price implied by expectations that revenue would fall 25.2% a year while profit margin improved to 23.3% and supported a future P/E of 51.9x. Supporters leaned on precision therapies, the PROTAC platform, and partnerships with groups like Novartis and Pfizer.
The bearish case leaned on a Fair Value of US$7, grounded in assumptions that revenue would decline 49.7% annually even if margin eventually reached 20.9% at a future P/E of 76.3x. Critics focused on a narrow pipeline, heavy reliance on milestone payments, and the risk that any setback in key programs or the Pfizer relationship could hit funding and delay any recovery.
What The Results Changed For Arvinas
Arvinas posted Q2 2026 revenue of US$249.7 million and net income of US$169.4 million, compared with Q2 2025 revenue of US$22.4 million and a loss of US$61.2 million. Net margin moved from a loss-making 273.2% to a positive 67.8%. The swing towards strong profitability supported the optimistic case on margins, although it did not settle how durable that level of earnings will be.
The key assumption tested here is how quickly profit margins can move. For another stock with a story built on future efficiency, track the reported net margin each quarter and compare it with the percentage path that earlier forecasts assumed.
What Arvinas' Share Slide Asks You To Believe Today
Arvinas now trades at US$7.09 from the start of the year, with the stock down 38.2%. The selected Narrative's Fair Value sits above the current price, which reflects that Narrative's judgment rather than a fact about where the shares should trade.
Its argument turns on whether early degrader programs, licensing deals and the cash runway can absorb delays without eroding future earnings quality. For the fall to look like an opportunity rather than a warning, a buyer today would need to believe current projects convert into steadier licensing and product income than cautious analysts expect.
"Although Arvinas has secured the first FDA approval of a PROTAC degrader and a Rigel licensing deal that generated US$62.5m of license revenue and a US$50m milestone from Pfizer in Q2 2026, the company now carries a US$52.7m liability for remaining VEPPANU development obligations and does not expect further revenue from the original Pfizer collaboration."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
Another Path Beyond Arvinas
Reading Arvinas puts biotech risk and timing in sharp focus. Nearby sits a business built around chronic diseases.
This other drug maker concentrates on diabetes, obesity and related conditions. It spreads bets across several treatment types instead of one platform.
Where Arvinas leans on precision degraders, this group emphasizes incretin therapies, combinations and potential vaccines.
The link is patients who need long term medical support and monitoring.
If that need keeps widening, a diversified treatment portfolio could matter more than any single breakthrough, and that is where the next Narrative goes.
That argument has a Narrative and a number behind it. → See the company one Narrative values 17% above its price
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ARVN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
